|
18 Mar 2022 |
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression
|
|
17 Mar 2022 |
Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
|
|
16 Mar 2022 |
Record Sales Of Therapeutic Antibodies in 2021 Pushed by Immuno-Oncology, Novel Anti-Inflammatory and Anti-SARS-CoV-2 Antibodies
|
|
15 Mar 2022 |
Update on US regulatory review of Fasenra in chronic rhinosinusitis with nasal polyps
|
|
15 Mar 2022 |
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne
|
|
12 Mar 2022 |
FDA Lifts Clinical Hold on Immunome’s IMM-BCP-01 IND Application for the Treatment of COVID-19
|
|
10 Mar 2022 |
Denali Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of DNL593 (PTV:PGRN) for Frontotemporal Dementia-Granulin (FTD-GRN)
|
|
10 Mar 2022 |
GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022
|
|
10 Mar 2022 |
Heidelberg Pharma Receives Milestone Payment from Partner Magenta for Dosing the First Patient with MGTA-117
|
|
09 Mar 2022 |
Epsilogen announces completion of oversubscribed £30.75 million ($41.20 million) Series B financing
|
|
09 Mar 2022 |
Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases
|
|
09 Mar 2022 |
Biocytogen Subsidiary, Eucure Biopharma, Announces the First Patient Dosing for a Phase I Multi-regional Clinical Trial of YH002 (Anti-OX40 mAb) in Combination with YH001 (Anti-CTLA-4 mAb) in Australia
|
|
09 Mar 2022 |
AbbVie Resolves HUMIRA® (adalimumab) U.S. Litigation with Alvotech
|
|
08 Mar 2022 |
Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy
|
|
08 Mar 2022 |
Alpine Immune Sciences Reports FDA Partial Clinical Hold on NEON-2 Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
|
|
08 Mar 2022 |
Preclinical Data of Prestige Biopharma’s First-in-Class Pancreatic Cancer Treatment, PBP1510, Presented in ESMO TAT 2022
|
|
08 Mar 2022 |
Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer
|
|
08 Mar 2022 |
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Significant Improvement in Distant Metastasis-Free Survival (DMFS) Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB and IIC Melanoma in Phase 3 KEYNOTE-716 Trial
|
|
06 Mar 2022 |
Eisai initiates submission of application data of lecanemab under the prior assessment consultation system in Japan with the aim of an earlier regulatory approval
|
|
05 Mar 2022 |
Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease
|
|
05 Mar 2022 |
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer
|
|
03 Mar 2022 |
Nirsevimab significantly protected infants against RSV disease in Phase III MELODY trial
|
|
02 Mar 2022 |
Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
|
|
01 Mar 2022 |
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
|
|
27 Feb 2022 |
Late-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic Esophagitis
|
